Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor
2023; Mary Ann Liebert, Inc.; Volume: 25; Issue: 9 Linguagem: Inglês
10.1089/dia.2023.0123
ISSN1557-8593
AutoresToni L. Cordero, Zheng Dai, Arcelia Arrieta, Fang Niu, Melissa Vella, John Shin, Andrew S. Rhinehart, Jennifer McVean, Scott W. Lee, Robert H. Slover, Gregory P. Forlenza, Dorothy I. Shulman, Rodica Pop‐Busui, James Thrasher, Mark Kipnes, Mark P. Christiansen, Bruce A. Buckingham, Catherine Pihoker, Jennifer L. Sherr, Kevin B. Kaiserman, Robert A. Vigersky,
Tópico(s)Diabetes and associated disorders
ResumoSafety and significant improvement in overall glycated hemoglobin (A1C) and percentage of time spent in (TIR), below (TBR), and above (TAR) glucose range were demonstrated in the pivotal trial of adolescents and adults using the MiniMed™ advanced hybrid closed-loop (AHCL) system with the adjunctive, calibration-required Guardian™ Sensor 3. The present study evaluated early outcomes of continued access study (CAS) participants who transitioned from the pivotal trial investigational system to the approved MiniMed™ 780G system with the non-adjunctive, calibration-free Guardian™ 4 Sensor (MM780G+G4S). Study data were presented alongside those of real-world MM780G+G4S users from Europe, the Middle East, and Africa.
Referência(s)